Research programme: diabetes therapy - Metabolex/Pfizer
Latest Information Update: 20 Dec 2013
At a glance
- Originator Metabolex; Pfizer
- Developer CymaBay Therapeutics; Pfizer
- Class
- Mechanism of Action Insulin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 10 Dec 2013 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
- 31 Dec 2012 No development reported - Preclinical for Type-2 diabetes mellitus in USA (PO)
- 04 Aug 2009 Preclinical development is ongoing in USA